Search Clinical Trials in the European Union

Duration
Visits
Phase
Injection
Benefits
Drugs
Locations
Clinical Specialty
1-20 of 2,120 trials

Adrenocortical Carcinoma: Mitotane Treatment Study

We are comparing standard mitotane therapy to mitotane combined with chemotherapy for patients at high risk of cancer recurrence after surgery. This study aims to find out which treatment helps patients live longer and maintain a better quality of life.

Adrenocortical Carcinoma6-12 monthsConfirmation phase (III)No PlaceboStandard MedicinesOncology

Urothelial Cancer: Disitamab Vedotin with Pembrolizumab

We are studying the effects of disitamab vedotin alone or with pembrolizumab in patients with HER2-positive urothelial cancer. This trial aims to see if these treatments can improve outcomes for those with advanced disease.

Bladder CancerEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Hodgkin Lymphoma: A2VD vs. ABVD Treatment Study

We are comparing two treatment options for patients with untreated early-stage Hodgkin lymphoma to see which may improve survival and reduce side effects. This study uses advanced imaging techniques to guide treatment decisions.

Classical Hodgkin LymphomaConfirmation phase (III)No PlaceboStandard MedicinesOncology

Acute Heart Failure: Treatment Comparison Study

We are testing different emergency treatments for pulmonary congestion in patients with acute heart failure. The goal is to see which method helps patients feel better faster after they arrive at the hospital.

Acute Heart Failure with Pulmonary Congestion>2 yearsMonitoring phase (IV)Investigational MedicinesPartially RemoteCardiologyInternal Medicine

Alzheimer's Disease and Down Syndrome: ACI-24.060 Study

We are testing a new treatment, ACI-24.060, to see if it is safe and can help generate an immune response in people with early Alzheimer's and adults with Down syndrome. This study will also look at its effects on brain amyloid levels.

Alzheimer's Disease>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsInvestigational MedicinesCost ReimbursementPartially RemoteNeurologyPsychiatry

Cholangiocarcinoma: Comparing RFA and PDT Treatments

We are studying whether radiofrequency ablation or photodynamic therapy helps patients with cholangiocarcinoma live longer. We’ll also look at how these treatments affect quality of life and any potential side effects.

Hilar Cholangiocarcinoma>2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteGastroenterologyOncology

Coronary Artery Disease Screening: Heart CT in Type 2 Diabetes

We are studying whether a heart CT scan can help find early signs of heart disease in people with type 2 diabetes. This may lead to better treatment options and improved heart health.

Type 2 DiabetesMonitoring phase (IV)No PlaceboStandard MedicinesCost ReimbursementCardiologyDiabetologyEndocrinology

FORE-PAIN Trial: Pain Relief Options for Trauma

We are studying whether intranasal and intravenous forms of fentanyl and esketamine can effectively relieve acute traumatic pain. The goal is to see if these options are as safe and satisfying as traditional intravenous fentanyl.

Acute Traumatic PainConfirmation phase (III)No PlaceboInvestigational MedicinesInternal MedicineOtolaryngologyPsychiatry

Cardiac AL Amyloidosis: [18F]florbetaben PET Imaging Study

We are evaluating a new imaging technique to improve the diagnosis of cardiac AL amyloidosis in patients. This study will help us understand how well it works compared to current diagnostic methods.

Cardiac AmyloidosisAL AmyloidosisATTR Amyloidosis>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCardiologyInternal Medicine

Kidney Transplant: Imlifidase for Highly Sensitized Children

We are studying whether imlifidase can help children with high sensitization receive a kidney transplant by improving compatibility with the donor. This trial will also look at kidney function and overall safety of the treatment.

Kidney Transplant Rejection>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesCost ReimbursementInternal MedicineNephrology

Rheumatoid Arthritis: Abatacept vs. TNF Inhibitors

We are comparing a new treatment strategy using abatacept to the standard TNF inhibitors for patients with rheumatoid arthritis. The goal is to see which approach helps more patients achieve remission.

Rheumatoid Arthritis6-12 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesInternal MedicineRheumatology

Diabetic Foot Infections: Contezolid Treatment Study

We are studying a new treatment called contezolid for adults with moderate to severe diabetic foot infections. The goal is to see if it is safer and more effective than the current standard treatment, linezolid.

Diabetic Foot Infection≤3 monthsConfirmation phase (III)6-10 visitsInvestigational MedicinesCost ReimbursementPartially RemoteEndocrinologyInfectious Diseases

Epidermolysis Bullosa: ABCB5+ Stem Cell Treatment

We are studying a new stem cell therapy for individuals with recessive dystrophic epidermolysis bullosa. The trial aims to see if this treatment is safe and effective compared to a placebo.

Epidermolysis Bullosa1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteDermatologyInternal Medicine

End-Stage Kidney Disease: CSL300 Treatment Study

We are investigating whether different doses of CSL300 can help reduce inflammation in adults with end-stage kidney disease undergoing dialysis. This study aims to understand its potential effects on heart health.

Atherosclerotic Cardiovascular Disease1-2 yearsEfficacy phase (II)Confirmation phase (III)>20 visitsInvestigational MedicinesCost ReimbursementCardiologyInternal MedicineNephrology

Parkinson's Disease: ACI-7104.056 Vaccine Study

We are testing a new vaccine to see if it is safe and can help improve symptoms in people with early-stage Parkinson's disease. The study will also look at how the vaccine affects certain biological markers related to the disease.

Early Stages of Parkinson's Disease>2 yearsEfficacy phase (II)11-15 visitsInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineNeurology

Acute Myeloid Leukemia: CPX-351 vs. Standard Chemotherapy

We are studying whether a new treatment called CPX-351 can help patients with specific types of acute myeloid leukemia achieve better remission compared to standard chemotherapy. This trial focuses on patients with de novo intermediate or adverse risk AML.

Acute Myeloid Leukemia>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Kidney Transplant: Belatacept vs. Traditional Immunosuppressants

We are studying if replacing standard medications with belatacept helps kidney transplant patients with early graft dysfunction. The goal is to see if this approach improves kidney function and reduces rejection risks.

Kidney Transplant1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesNephrology

Chronic Lymphocytic Leukemia: Venetoclax and Epcoritamab Study

We are studying a combination of venetoclax and epcoritamab in patients with relapsed or refractory CLL or SLL. The goal is to see if this treatment improves disease control and overall survival compared to existing options.

Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementHematologyOncology

Crohn's Disease: Comparing Biological Therapies After Surgery

We are studying two ways to start biological therapy after surgery for Crohn's disease to see which better prevents disease recurrence. This trial involves adults who have had an ileocolonic resection.

Crohn's Disease1-2 yearsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementGastroenterologyInternal Medicine

Etripamil Nasal Spray for Pediatric Heart Condition

We are studying whether a nasal spray can help stop episodes of a fast heart rate in children aged 6 to 17. The trial also looks at how safe the spray is for these young patients.

Paroxysmal Supraventricular Tachycardia≤3 monthsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCardiologyPediatrics